LAUSR

fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative). Br J Dermatol 2016; 175:69–79. 4 Cork MJ, Britton J, Butler L et al. Comparison of parent knowledge, therapy utilization and severity of atopic eczema before and after explanation and demonstration of topical therapies by a specialist dermatology nurse. Br J Dermatol 2003; 149:582–9. 5 Beattie PE, Lewis-Jones MS. Parental knowledge of topical therapies in the treatment of childhood atopic dermatitis. Clin Exp Dermatol 2003; 28:549–53. 6 Gielen AC, McDonald EM, Gary TL et al. Using the PRECEDE/PROCEED model to apply health behavior theories. In: Health Behavior and Health Education: Theory, Research and Practice (Glanz K, Rimer BK, Viswanath K, eds), 4th edn. San Francisco: Jossey-Bass Public Health, 2008; 407–33. 7 Wan TTH, Terry A, McKee B, Kattan W. KMAP-O framework for care management research of patients with type 2 diabetes. World J Diabetes 2017; 8:165–71. 8 Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol 2000; 142:931–6. 9 El Hachem M, Gesualdo F, Ricci G et al. Topical corticosteroid phobia in parents of pediatric patients with atopic dermatitis: a multicentre survey. Ital J Pediatr 2017; 43:22. 10 Patel NU, D’Ambra V, Feldman SR. Increasing adherence with topical agents for atopic dermatitis. Am J Clin Dermatol 2017; 18:323–32.